Ongoing projects
- Best practice handbook for the humanization of pharmacy services in the care of patients with rare diseases. Access the humanization handbook
- Horizon scanning systems for orphan drugs
- Access the 1st report (February 2020)
- Access the 2nd report (December 2020)
- Access the 3rd report (June 2021)
- Access the 4th report (December 2021)
- Access the 5th report on non-oncology drugs (June 2022)
- Access the 6th report (December 2022)
- Analysis and evaluation of the multiple criteria decision analysis (MCDA) methodology applied to the evaluation of rare diseases. Access the MCDA handbook
- Analysis of the evaluations of orphan drugs carried out in Spain between 2018-2022 using Multicriteria Decision Analysis (MCDA). Access the analysis
- Hospital pharmacy monograph for patients with rare diseases. Access the monograph
Past projects
- Economic impact of the treatment of rare diseases.
- Evaluating the health outcomes of eculizumab in patients with nocturnal paroxysmal hemoglobinuria.
- Analyzing the effectiveness and efficiency of eculizumab in patients with NPH in Spain.
- “How to can the hospital’s pharmacy contribute to informing and activating patients with rare diseases and their family members: a qualitative research project”. See preliminary document